cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1668Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMАнтиангинальная терапия больных стабильной стенокардией: фокус на снижение частоты сердечных сокращенийAntianginal treatment of stable angina: focus on heart rate reductionЛоматинЮ. М.LopatinYu. M.lopatin@sprint8v.com.ruВолгоградский государственный медицинский университет, Волгоградский областной кардиологический центр. ВолгоградVolgograd State Medical University, Volgograd Regional Cardiology Center. Volgograd200601011970578690Copyright © Ломатин Ю.М., 19701970Ломатин Ю.М.Lopatin Y.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1668

Статья посвящена современной позиции снижения частоты сердечных сокращений как нового подхода в лечении больных стабильной стенокардией (СС). Проанализирован алгоритм медикаментозного лечения больных СС, предложенный Европейским Обществом Кардиологов 2006.

 

The article is focused on modern approaches to heart rate reduction, as a new method for stable angina (SA) management. The algorhithm of SA pharmaceutical treatment, by the European Society of Cardiology (2006), is analyzed.

стабильная стенокардияβ-адреноблокаторыантагонисты кальцияингибитор f-каналов синусового узла – ивабрадинstable anginabeta-adrenoblockerscalcium antagonistssinus node f-channel inhibitor – ivabradinReferencesDiaz A., Bourassa M.G., Guertin M-C., et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.Diaz A., Bourassa M.G., Guertin M-C., et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.Patel S.R., Breall J.A., Diver D.J., et al. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11:467-72.Patel S.R., Breall J.A., Diver D.J., et al. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11:467-72.Heidland U.E., Strauer B.E. Left ventricular muscle mass and eleva ed heart rate associated with coronary plaque distruption. Circulation 2001; 104: 1477-82.Heidland U.E., Strauer B.E. Left ventricular muscle mass and eleva ed heart rate associated with coronary plaque distruption. Circulation 2001; 104: 1477-82.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.Recommendation of the Task Force of the European Society of cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394-413.Recommendation of the Task Force of the European Society of cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394-413.Thadani U. Treatment of stable angina. Curr Opin Cardiol 1999; 14: 349-58.Thadani U. Treatment of stable angina. Curr Opin Cardiol 1999; 14: 349-58.Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of cardiology. Eur Heart J 2004; 25: 1341-62.Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of cardiology. Eur Heart J 2004; 25: 1341-62.Purcell Y., Fox K. Selective and specific If inhibition: new perspectives. Medicographia 2005; 27: 51-5.Purcell Y., Fox K. Selective and specific If inhibition: new perspectives. Medicographia 2005; 27: 51-5.Daly CA, Clements F, Lopez Sendoz JL, et al. The initial manage8 ment of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005; 26: 1011822.Daly CA, Clements F, Lopez Sendoz JL, et al. The initial manage8 ment of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005; 26: 1011822.Daly C.A., Clements F., Lopez Sendoz J.L., et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27: 1298-304.Daly C.A., Clements F., Lopez Sendoz J.L., et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27: 1298-304.Tendera M. If inhibition: from pure heart reduction to treatment of stable angina. Eur Heart J 2005; Suppl. H: H3-6.Tendera M. If inhibition: from pure heart reduction to treatment of stable angina. Eur Heart J 2005; Suppl. H: H3-6.Borer J.D., Fox K., Jalion P., et al. Antianginal and antiischemic effects of ivabradin, an If inhibitor in stable angina. Circulation 2003; 107: 817-23.Borer J.D., Fox K., Jalion P., et al. Antianginal and antiischemic effects of ivabradin, an If inhibitor in stable angina. Circulation 2003; 107: 817-23.Ruzyllo W., Ford I., Tendera M., et al. Antianginal and antiischemic effects of If current inhibitor ivabradine compared to amlopdipine as monotherapy in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multicenter trial. Eur Heart J 2004; 25: Abstr 867.Ruzyllo W., Ford I., Tendera M., et al. Antianginal and antiischemic effects of If current inhibitor ivabradine compared to amlopdipine as monotherapy in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multicenter trial. Eur Heart J 2004; 25: Abstr 867.Tardif J-C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heat J 2005; 26: 2529-36.Tardif J-C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heat J 2005; 26: 2529-36.Tardif J-C., Fox K., Tendera M., et al. Absence of rebound phenomenon after abrupt discontinuation of ivabradine, a new selective and specific If inhibitor, in patients with coronary artery disease. Eur Heart J 2005; 26: 580.Tardif J-C., Fox K., Tendera M., et al. Absence of rebound phenomenon after abrupt discontinuation of ivabradine, a new selective and specific If inhibitor, in patients with coronary artery disease. Eur Heart J 2005; 26: 580.Diaz A., Tardif J-C. Clinical applications of exclusive heart rate reduction in emergence cardiology. Medicographia 2005; 27: 82-6.Diaz A., Tardif J-C. Clinical applications of exclusive heart rate reduction in emergence cardiology. Medicographia 2005; 27: 82-6.

The authors declare that there are no conflicts of interest present.